Keywords
Abstract
Teri onkologik kasalliklari zamonaviy tibbiyotning dolzarb muammolaridan biri bo‘lib, ularning erta aniqlanishi bemorlarning yashash prognozi va hayot sifatini sezilarli darajada yaxshilaydi. Ushbu maqolada teri saratonining etiologik omillari, klinik kechishi hamda erta diagnostika usullarining samaradorligi ilmiy jihatdan tahlil qilindi. Tadqiqotlar shuni ko‘rsatadiki, ultrabinafsha nurlanishning uzoq muddatli ta’siri, genetik mutatsiyalar, immun tizimning susayishi va kimyoviy kanserogenlar teri o‘smalarining asosiy sabablaridan hisoblanadi. Klinik jihatdan melanoma, bazal hujayrali va yassi hujayrali karsinomalar eng ko‘p uchraydi. Erta diagnostika usullari orasida dermatoskopiya, biopsiya, konfokal mikroskopiya va raqamli tasvirlash texnologiyalari yuqori sezgirlikka ega ekanligi aniqlangan. Statistik ma’lumotlarga ko‘ra, erta bosqichda aniqlangan melanoma bemorlarida 5 yillik yashash darajasi 90–95 foizni tashkil etsa, kech bosqichlarda bu ko‘rsatkich keskin kamayadi. Shuningdek, sun’iy intellekt asosidagi diagnostik tizimlar so‘nggi yillarda aniqlikni 15–20 foizga oshirgani qayd etilgan.
References
. World Health Organization. (2023). Skin cancers: Key facts and prevention strategies. WHO Press
2. American Cancer Society. (2024). Cancer facts & figures 2024. American Cancer Society.
3. Siegel, R. L., Miller, K. D., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48.
4. Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global cancer statistics 2020. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
5. Leiter, U., Keim, U., & Garbe, C. (2020). Epidemiology of skin cancer. Advances in Experimental Medicine and Biology, 1268, 1–18.
6. Marks, R. (2021). Epidemiology of non-melanoma skin cancer. Medical Journal of Dermatology, 45(2), 101–110.
7. Brash, D. E. (2019). UV-induced skin cancer and DNA damage. Journal of Investigative Dermatology, 139(6), 1235–1243.
8. Rees, J. L. (2020). Genetics of melanoma. Nature Reviews Cancer, 20(2), 111–125.
9. Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2021). Melanoma: From mutations to medicine. Genes & Development, 35(9–10), 575–590.
10. Ferris, L. K. (2022). Artificial intelligence in dermatology. JAMA Dermatology, 158(4), 399–401.
11. Esteva, A., Kuprel, B., Novoa, R. A., et al. (2019). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115–118.
12. Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46.
13. Slominski, A. T., Zmijewski, M. A., & Pawelek, J. (2021). Melanoma biology and progression. Endocrine Reviews, 42(2), 123–150.
14. Garbe, C., & Eigentler, T. K. (2020). Diagnosis and treatment of melanoma. The Lancet, 395(10226), 195–207.
15. Koh, H. K. (2019). Skin cancer prevention and control. New England Journal of Medicine, 381(1), 58–65.
16. Rogers, H. W., Weinstock, M. A., Feldman, S. R., & Coldiron, B. M. (2021). Incidence of nonmelanoma skin cancer. JAMA Dermatology, 157(3), 265–272.
17. Bradford, P. T. (2018). Skin cancer in skin of color. Cancer, 124(5), 1061–1072.
18. Dummer, R., Hauschild, A., Lindenblatt, N., et al. (2021). Cutaneous melanoma. Nature Reviews Disease Primers, 7(1), 1–25.
19. Whiteman, D. C., Green, A. C., & Olsen, C. M. (2020). The growing burden of skin cancer. Nature Reviews Cancer, 20(8), 473–486.
20. Berman, B., & Cockerell, C. J. (2019). Pathology and management of skin tumors. Dermatologic Clinics, 37(3), 277–289.*